TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid(TM))(MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy
Brief Summary: This randomized phase III trial studies melphalan and prednisone with thalidomide to see how well it works compared to melphalan and prednisone together with lenalidomide in treating patients with newly diagnosed multiple myeloma. Drugs used in chemotherapy, such as melphalan and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Thalidomide and lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. It is not yet known whether melphalan and prednisone are more effective when given together with thalidomide or lenalidomide in treating multiple myeloma.


Options:
A: Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): N/A
C: Arm Label: A (Thalidomide & Dexamethasone); Type: EXPERIMENTAL; Interventions: Drug: A (Thalidomide + Dexamethasone) | Arm Label: B (Dexamethasone and placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: B (Placebo + Dexamethasone) | Intervention Type: DRUG; Name: A (Thalidomide + Dexamethasone); Assigned to Arm(s): A (Thalidomide & Dexamethasone) | Intervention Type: DRUG; Name: B (Placebo + Dexamethasone); Assigned to Arm(s): B (Dexamethasone and placebo)
D: Arm Label: Arm I (thalidomide); Type: ACTIVE_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Drug: Melphalan, Drug: Prednisone, Other: Quality-of-Life Assessment, Drug: Thalidomide | Arm Label: Arm II (lenalidomide); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Drug: Lenalidomide, Drug: Melphalan, Drug: Prednisone | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (thalidomide), Arm II (lenalidomide) | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Arm II (lenalidomide) | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): Arm I (thalidomide), Arm II (lenalidomide) | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Arm I (thalidomide), Arm II (lenalidomide) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (thalidomide) | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): Arm I (thalidomide)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acclimatization Mechanisms During Ascent to 7500m. Effects of Ascent Protocol on Acute Mountain Sickness and Cardiorespiratory Physiology
Brief Summary: The trial evaluates the role of ascent protocol on acute mountain sickness and cardio-respiratory physiology during an ascent to Muztagh Ata (7546m). Two groups of mountaineers ascend with different acclimatization time to the summit. The prevalence and severity of symptoms of acute mountain sickness are evaluated along with physiologic variables.


Options:
A: Arm Label: Acetazolamide; Type: EXPERIMENTAL; Interventions: Drug: Acetazolamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lactose monohydrate | Intervention Type: DRUG; Name: Acetazolamide; Assigned to Arm(s): Acetazolamide | Intervention Type: DRUG; Name: Lactose monohydrate; Assigned to Arm(s): Placebo
B: Arm Label: Telmisartan/nifedipine; Type: EXPERIMENTAL; Interventions: Drug: Telmisartan, Drug: Nifedipine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: ascent protocol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ascent protocol | Intervention Type: BEHAVIORAL; Name: ascent protocol; Assigned to Arm(s): 1, 2
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Aminophylline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aminophylline | Arm Label: Methazolamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methazolamide | Arm Label: Aminophylline+Methazolamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aminophylline+Methazolamide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Aminophylline; Assigned to Arm(s): Aminophylline | Intervention Type: DRUG; Name: Methazolamide; Assigned to Arm(s): Methazolamide | Intervention Type: DRUG; Name: Aminophylline+Methazolamide; Assigned to Arm(s): Aminophylline+Methazolamide

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acclimatization Mechanisms During Ascent to 7500m. Effects of Ascent Protocol on Acute Mountain Sickness and Cardiorespiratory Physiology
Brief Summary: The trial evaluates the role of ascent protocol on acute mountain sickness and cardio-respiratory physiology during an ascent to Muztagh Ata (7546m). Two groups of mountaineers ascend with different acclimatization time to the summit. The prevalence and severity of symptoms of acute mountain sickness are evaluated along with physiologic variables.


Options:
A: Arm Label: Telmisartan/nifedipine; Type: EXPERIMENTAL; Interventions: Drug: Telmisartan, Drug: Nifedipine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen | Arm Label: acetazolamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetazolamide | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Ibuprofen | Intervention Type: DRUG; Name: Acetazolamide; Assigned to Arm(s): acetazolamide
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: ascent protocol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ascent protocol | Intervention Type: BEHAVIORAL; Name: ascent protocol; Assigned to Arm(s): 1, 2
D: Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acclimatization Mechanisms During Ascent to 7500m. Effects of Ascent Protocol on Acute Mountain Sickness and Cardiorespiratory Physiology
Brief Summary: The trial evaluates the role of ascent protocol on acute mountain sickness and cardio-respiratory physiology during an ascent to Muztagh Ata (7546m). Two groups of mountaineers ascend with different acclimatization time to the summit. The prevalence and severity of symptoms of acute mountain sickness are evaluated along with physiologic variables.


Options:
A: Arm Label: Telmisartan/nifedipine; Type: EXPERIMENTAL; Interventions: Drug: Telmisartan, Drug: Nifedipine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: ascent protocol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ascent protocol | Intervention Type: BEHAVIORAL; Name: ascent protocol; Assigned to Arm(s): 1, 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: dexamethasone 8 mg bid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tadalafil 10mg bid; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 250mcg Twice Daily Compared With Placebo for 8 Weeks in Adolescent and Adult Subjects With Persistent Asthma Symptomatic on Low-Dose ICS Therapy
Brief Summary: This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.


Options:
A: Arm Label: Subjects receiving fluticasone foroate/ vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone foroate/ vilanterol, Drug: Fluticasone foroate, Drug: Vilanterol | Arm Label: Subjects receiving fluticasone foroate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone foroate | Arm Label: Subjects receiving vilanterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vilanterol | Arm Label: Subjects receiving placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone foroate/ vilanterol; Assigned to Arm(s): Subjects receiving fluticasone foroate/ vilanterol | Intervention Type: DRUG; Name: Fluticasone foroate; Assigned to Arm(s): Subjects receiving fluticasone foroate, Subjects receiving fluticasone foroate/ vilanterol | Intervention Type: DRUG; Name: Vilanterol; Assigned to Arm(s): Subjects receiving fluticasone foroate/ vilanterol, Subjects receiving vilanterol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Subjects receiving placebo
B: Arm Label: GW642444M/lactose; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: GW642444, Drug: Magnesium Stearate | Arm Label: GW642444M/MgSt; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: GW642444, Drug: Magnesium Stearate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: GW642444, Drug: Magnesium Stearate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): GW642444M/MgSt, GW642444M/lactose, Placebo | Intervention Type: DRUG; Name: GW642444; Assigned to Arm(s): GW642444M/MgSt, GW642444M/lactose, Placebo | Intervention Type: DRUG; Name: Magnesium Stearate; Assigned to Arm(s): GW642444M/MgSt, GW642444M/lactose, Placebo
C: Arm Label: Arm 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: GW685698X | Intervention Type: DRUG; Name: GW685698X; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Arm 1
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: GW685698X 200mcg,GW685698X 200mcg and 400mcg | Intervention Type: DRUG; Name: GW685698X 200mcg,GW685698X 200mcg and 400mcg; Assigned to Arm(s): Arm 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Overweight and Obese Patients With Type 2 Diabetes Mellitus Managed With Oral Hypoglycemic Agent(s)
Brief Summary: The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients with Type II diabetes mellitus treated with metformin, sulfonylurea (SFU), or either agent in combination with other oral hypoglycemic agents.


Options:
A: Intervention Type: DRUG; Name: Rimonabant (SR141716); Assigned to Arm(s): N/A
B: Arm Label: Lorcaserin 10 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Lorcaserin 10 mg once daily (QD) | Arm Label: Lorcaserin 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Lorcaserin 10 mg twice a day (BID) | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching Placebo | Intervention Type: DRUG; Name: Lorcaserin 10 mg once daily (QD); Assigned to Arm(s): Lorcaserin 10 mg QD | Intervention Type: DRUG; Name: Lorcaserin 10 mg twice a day (BID); Assigned to Arm(s): Lorcaserin 10 mg BID | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): Matching Placebo
C: Arm Label: Liraglutide 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: NB16; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Behavioral: Ancillary therapy | Arm Label: NB32; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Behavioral: Ancillary therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Ancillary therapy | Intervention Type: DRUG; Name: Naltrexone SR 16 mg/Bupropion SR 360 mg /day; Assigned to Arm(s): NB16 | Intervention Type: DRUG; Name: Naltrexone SR 32 mg/Bupropion SR 360 mg /day; Assigned to Arm(s): NB32 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Ancillary therapy; Assigned to Arm(s): NB16, NB32, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment With Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence: Results of a Randomized Placebo-Controlled Phase III Clinical Trial
Brief Summary: The study was conducted between 2004 and 2006 to prove efficacy and tolerability of the antimuscarinic propiverine compared to placebo in children suffering from non-neurogenic overactive bladder and urinary incontinence.


Options:
A: Arm Label: Surgical; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery | Arm Label: Medical Treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Medical Treatment | Intervention Type: PROCEDURE; Name: Surgery; Assigned to Arm(s): Surgical | Intervention Type: PROCEDURE; Name: Medical Treatment; Assigned to Arm(s): Medical Treatment
B: Arm Label: Placebo Children; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Urotherapy | Arm Label: Solifenacin Succinate Suspension Children; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin Succinate Suspension, Behavioral: Urotherapy | Arm Label: Placebo Adolescents; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Urotherapy | Arm Label: Solifenacin Succinate Suspension Adolescents; Type: PLACEBO_COMPARATOR; Interventions: Drug: Solifenacin Succinate Suspension, Behavioral: Urotherapy | Intervention Type: DRUG; Name: Solifenacin Succinate Suspension; Assigned to Arm(s): Solifenacin Succinate Suspension Adolescents, Solifenacin Succinate Suspension Children | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Adolescents, Placebo Children | Intervention Type: BEHAVIORAL; Name: Urotherapy; Assigned to Arm(s): Placebo Adolescents, Placebo Children, Solifenacin Succinate Suspension Adolescents, Solifenacin Succinate Suspension Children
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mictonetten 5 mg, coated tablet | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mictonetten 5 mg, coated tablet; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Intervention Type: DEVICE; Name: Nerve stimulator; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Administered Once Daily and Fluticasone Propionate Inhalation Powder 100mcg Twice Daily Compared With Placebo for 8 Weeks in Adolescent and Adult Subjects With Persistent Asthma Symptomatic on Non-Steroidal, Asthma Therapy
Brief Summary: This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.


Options:
A: Arm Label: Fluticasone Furoate/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/Vilanterol Inhalation Powder, Other: Placebo Inhalation Powder 2 | Arm Label: Fluticasone Furoate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Furoate Inhalation Powder, Other: Placebo Inhalation Powder 2 | Arm Label: Fluticasone Propionate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Propionate Inhalation Powder, Other: Placebo Inhalation Powder 1 | Intervention Type: DRUG; Name: Fluticasone Furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate/Vilanterol | Intervention Type: DRUG; Name: Fluticasone Furoate Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate | Intervention Type: DRUG; Name: Fluticasone Propionate Inhalation Powder; Assigned to Arm(s): Fluticasone Propionate | Intervention Type: OTHER; Name: Placebo Inhalation Powder 1; Assigned to Arm(s): Fluticasone Propionate | Intervention Type: OTHER; Name: Placebo Inhalation Powder 2; Assigned to Arm(s): Fluticasone Furoate, Fluticasone Furoate/Vilanterol
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: GW685698X 200mcg,GW685698X 200mcg and 400mcg | Intervention Type: DRUG; Name: GW685698X 200mcg,GW685698X 200mcg and 400mcg; Assigned to Arm(s): Arm 1
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: GW685698X; Type: EXPERIMENTAL; Interventions: Drug: GW685698X | Intervention Type: DRUG; Name: GW685698X; Assigned to Arm(s): GW685698X | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: QMF149 Twisthaler® 500/400; Type: EXPERIMENTAL; Interventions: Drug: QMF149 Twisthaler® | Arm Label: Mometasone Twisthaler®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mometasone Twisthaler® | Intervention Type: DRUG; Name: QMF149 Twisthaler®; Assigned to Arm(s): QMF149 Twisthaler® 500/400 | Intervention Type: DRUG; Name: Mometasone Twisthaler®; Assigned to Arm(s): Mometasone Twisthaler®

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a 24 Hour Phone Line on the Rate of Suicide Attempts in Borderline Patients
Brief Summary: This randomized multicentric clinical trial assesses the effectiveness of 24 hour phone line on the rate of suicide attempts and self-injurious behaviors in borderline patients.


Options:
A: Arm Label: Intensive Group Analytic Psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive Group Analytic Psychotherapy | Arm Label: Intensive GCBT; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive transdiagnostic cognitive-behavioral group therapy | Arm Label: Wait-list control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intensive Group Analytic Psychotherapy; Assigned to Arm(s): Intensive Group Analytic Psychotherapy | Intervention Type: BEHAVIORAL; Name: Intensive transdiagnostic cognitive-behavioral group therapy; Assigned to Arm(s): Intensive GCBT
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: 24 hour phone line | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: treatment as usual | Intervention Type: OTHER; Name: 24 hour phone line; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: treatment as usual; Assigned to Arm(s): 2
C: Arm Label: Mindfulness skills; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness skills training | Arm Label: Interpersonal effectiveness skills; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interpersonal Effectiveness skills training | Intervention Type: BEHAVIORAL; Name: Mindfulness skills training; Assigned to Arm(s): Mindfulness skills | Intervention Type: BEHAVIORAL; Name: Interpersonal Effectiveness skills training; Assigned to Arm(s): Interpersonal effectiveness skills
D: Arm Label: Iconic Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Emotional regulation | Arm Label: Support therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Emotional regulation | Intervention Type: BEHAVIORAL; Name: Emotional regulation; Assigned to Arm(s): Iconic Therapy, Support therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a 24 Hour Phone Line on the Rate of Suicide Attempts in Borderline Patients
Brief Summary: This randomized multicentric clinical trial assesses the effectiveness of 24 hour phone line on the rate of suicide attempts and self-injurious behaviors in borderline patients.


Options:
A: Arm Label: S-DBT; Type: EXPERIMENTAL; Interventions: Behavioral: Standard dialectical behavior therapy (SDBT) | Arm Label: DBT-I; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual DBT with no DBT group sessions (DBT-I) | Arm Label: DBT-S; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Group Skills DBT with no DBT individual sessions (DBT-S) | Intervention Type: BEHAVIORAL; Name: Standard dialectical behavior therapy (SDBT); Assigned to Arm(s): S-DBT | Intervention Type: BEHAVIORAL; Name: Individual DBT with no DBT group sessions (DBT-I); Assigned to Arm(s): DBT-I | Intervention Type: BEHAVIORAL; Name: Group Skills DBT with no DBT individual sessions (DBT-S); Assigned to Arm(s): DBT-S
B: Arm Label: Dialectical Behavior Therapy DBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DBT | Arm Label: CAMS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CAMS | Intervention Type: BEHAVIORAL; Name: DBT; Assigned to Arm(s): Dialectical Behavior Therapy DBT | Intervention Type: BEHAVIORAL; Name: CAMS; Assigned to Arm(s): CAMS
C: Arm Label: Relaxation group; Type: ACTIVE_COMPARATOR; Interventions: Other: Relaxation group | Arm Label: Psychoeducational group; Type: EXPERIMENTAL; Interventions: Behavioral: Interventional group : PEPSUI psychoeducational program | Intervention Type: BEHAVIORAL; Name: Interventional group : PEPSUI psychoeducational program; Assigned to Arm(s): Psychoeducational group | Intervention Type: OTHER; Name: Relaxation group; Assigned to Arm(s): Relaxation group
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: 24 hour phone line | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: treatment as usual | Intervention Type: OTHER; Name: 24 hour phone line; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: treatment as usual; Assigned to Arm(s): 2

Answer: D